230 related articles for article (PubMed ID: 35138582)
41. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
[TBL] [Abstract][Full Text] [Related]
42. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
43. Patient-related characteristics predict prostate cancers in men with PI-RADS 4-5 to further optimize the diagnostic performance of MRI.
Xiang L; Ma S; Xu Y; Jiang L; Guo H; Liu H; Liu Y
Abdom Radiol (NY); 2023 Dec; 48(12):3766-3773. PubMed ID: 37776336
[TBL] [Abstract][Full Text] [Related]
44. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Haj-Mirzaian A; Burk KS; Lacson R; Glazer DI; Saini S; Kibel AS; Khorasani R
JAMA Netw Open; 2024 Mar; 7(3):e244258. PubMed ID: 38551559
[TBL] [Abstract][Full Text] [Related]
45. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
[TBL] [Abstract][Full Text] [Related]
46. Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.
Cussenot O; Renard-Penna R; Montagne S; Ondet V; Pilon A; Guechot J; Comperat E; Hamdy F; Lamb A; Cancel-Tassin G
BJU Int; 2023 Jun; 131(6):745-754. PubMed ID: 36648168
[TBL] [Abstract][Full Text] [Related]
47. Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
Stevens E; Truong M; Bullen JA; Ward RD; Purysko AS; Klein EA
Urol Oncol; 2020 Nov; 38(11):846.e9-846.e16. PubMed ID: 32576527
[TBL] [Abstract][Full Text] [Related]
48. PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions.
Kwe J; Baunacke M; Boehm K; Platzek I; Thomas C; Borkowetz A
World J Urol; 2024 Feb; 42(1):84. PubMed ID: 38363332
[TBL] [Abstract][Full Text] [Related]
49. Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies.
Kortenbach KC; Løgager V; Thomsen HS; Boesen L
Abdom Radiol (NY); 2023 Feb; 48(2):688-693. PubMed ID: 36318331
[TBL] [Abstract][Full Text] [Related]
50. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
51. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
Haack M; Miksch V; Tian Z; Duwe G; Thomas A; Borkowetz A; Stroh K; Thomas C; Haferkamp A; Höfner T; Boehm K
World J Urol; 2022 Dec; 40(12):2947-2954. PubMed ID: 36318314
[TBL] [Abstract][Full Text] [Related]
52. MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men.
Tan TW; Png KS; Lee CH; Yuwono A; Yeow Y; Chong KT; Lee YM; Tan CH; Tan YK
J Endourol; 2017 Nov; 31(11):1111-1116. PubMed ID: 28797178
[TBL] [Abstract][Full Text] [Related]
53. Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category ≥3.
Shoji S; Kaya T; Tanaka Y; Uemura K; Kusaka T; Takahashi K; Yuzuriha S; Kano T; Hanada I; Umemoto T; Ogawa T; Nakano M; Kawakami M; Nitta M; Hasegawa M; Hashida K; Hasebe T; Kaneko T; Okada J; Asai S; Miyajima A
J Urol; 2023 Jan; 209(1):187-197. PubMed ID: 36067387
[TBL] [Abstract][Full Text] [Related]
54. Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative.
Drevik J; Dalimov Z; Uzzo R; Danella J; Guzzo T; Belkoff L; Raman J; Tomaszewski J; Trabulsi E; Reese A; Singer EA; Syed K; Jacobs B; Correa A; Smaldone M; Ginzburg S
Urol Oncol; 2022 Nov; 40(11):490.e1-490.e6. PubMed ID: 36163229
[TBL] [Abstract][Full Text] [Related]
55. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract][Full Text] [Related]
56. Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI.
Press BH; Khajir G; Ghabili K; Leung C; Fan RE; Wang NN; Leapman MS; Sonn GA; Sprenkle PC
Urology; 2021 Sep; 155():96-100. PubMed ID: 34087311
[TBL] [Abstract][Full Text] [Related]
57. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
[TBL] [Abstract][Full Text] [Related]
58. Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4.
Ghabili K; Swallow M; Sherrer RL; Syed JS; Khajir G; Gordetsky JB; Leapman MS; Rais-Bahrami S; Sprenkle PC
Urology; 2019 Dec; 134():173-180. PubMed ID: 31419433
[TBL] [Abstract][Full Text] [Related]
59. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
[TBL] [Abstract][Full Text] [Related]
60. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
